Sonya Knight, DO
Clinical Neurophysiology · Blue Bell, PANPI 1558495283
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $13,326 of the $18,611 with a category attached, or 71.6%. Otsuka America Pharmaceutical, Inc. accounts for 78.9% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $8,744 and has fallen 84.7% since, to $1,339 in 2025.
Across 230 payments — averaging $80.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$15K
- AbbVie$1K
- Brainsway USA Inc$753
- Teva Pharmaceuticals USA, Inc.$407
- Neurocrine Biosciences, Inc.$279
- Jazz Pharmaceuticals Inc.$150
- plus $1K from 23 others
What the payments were for
- Consulting fees$1501%
- Speaking & faculty fees$13,32672%
- Travel & lodging$1,5758%
- Food & beverage$3,30118%
- Education$2591%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 35 | $14,680 |
| AbbVie(2 entities) | 109 | $1,152 |
| Brainsway USA Inc | 2 | $753 |
| Teva Pharmaceuticals USA, Inc. | 8 | $407 |
| Neurocrine Biosciences, Inc. | 14 | $279 |
| Jazz Pharmaceuticals Inc. | 1 | $150 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $149 |
| Lundbeck LLC | 10 | $147 |
| Bausch Health US, LLC | 6 | $129 |
| Pfizer | 5 | $114 |
| Upsher-smith Laboratories LLC | 4 | $81 |
| Merck | 4 | $59 |
| Amneal Pharmaceuticals LLC | 3 | $55 |
| Amgen | 3 | $48 |
| Harmony Biosciences LLC | 1 | $48 |
| Vanda Pharmaceuticals Inc. | 2 | $42 |
| Sunovion Pharmaceuticals Inc. | 3 | $42 |
| Johnson & Johnson | 1 | $38 |
| Collegium Pharmaceutical, Inc. | 2 | $36 |
| Supernus Pharmaceuticals, Inc. | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| UCB, Inc. | 1 | $23 |
| Neurelis, Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Almatica Pharma LLC | 1 | $16 |
| SK Life Science, Inc. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few clinical neurophysiology providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XyremSodium Oxybate | 12 | $340,712 |
| CaplytaLumateperone Tosylate | 20 | $32,705 |
| VraylarCariprazine Hcl | 17 | $25,028 |
| QuliptaAtogepant | 23 | $23,147 |
| AuvelityDextromethorphan Hbr/Bupropion | 13 | $14,829 |
| Aimovig AutoinjectorErenumab-Aooe | 19 | $14,028 |
| Dalfampridine ErDalfampridine | 13 | $5,572 |
| Lamotrigine ErLamotrigine | 17 | $5,223 |
| Duloxetine Hcl | 112 | $3,799 |
| Vilazodone Hcl | 41 | $2,825 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 56 | $1,966 |
| Sertraline Hcl | 161 | $1,934 |
| Temazepam | 41 | $1,827 |
| Clonazepam | 183 | $1,663 |
| Bupropion XlBupropion Hcl | 40 | $1,607 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Qulipta | $1,152 | $48,17440 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $149 | $32,70520 claims |
| Axsome Therapeutics, Inc.Auvelity | $14 | $14,82913 claims |
| Almatica Pharma LLCSertraline Hcl | $16 | $1,934161 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Pennsylvaniaon file to place this against a meaningful peer group, so we don't.
Other clinical neurophysiology in Blue Bell
- Saira SaadHarrisburg$48K
- Zachary SimmonsHershey$43K
- Sandeep RanaPittsburgh$30K
- Venkatraman ThulasiBethlehem$29K
- Venkata JakkampudiHershey$7K
- Charles BaePhiladelphia$7K
- Jagdish ShahMechanicsburg$3K
- Laxmi ShahMonroeville$2K
- Cynthia CorrellDanville$2K
- Karen CarvalhoPhiladelphia$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.